Dupilumab in the treatment of dystrophic epidermolysis bullosa: off-label use in a pediatric patient

Int J Dermatol. 2023 Dec;62(12):e617-e618. doi: 10.1111/ijd.16821. Epub 2023 Aug 25.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Child
  • Epidermolysis Bullosa Dystrophica* / complications
  • Epidermolysis Bullosa Dystrophica* / drug therapy
  • Epidermolysis Bullosa*
  • Humans
  • Off-Label Use
  • Skin

Substances

  • dupilumab
  • Antibodies, Monoclonal, Humanized